Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide epigenetic changes of leukemia cell lines in reponse to byrostatin treatment

ABSTRACT: Genome-wide epigenetic changes of leukemia cell lines in reponse to byrostatin treatment

PROVIDER: PRJNA793905 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17417700_1.fastq.gz	Fastqsanger.gz
	SRR17417700_2.fastq.gz	Fastqsanger.gz
	SRR17417701_1.fastq.gz	Fastqsanger.gz
	SRR17417701_2.fastq.gz	Fastqsanger.gz
	SRR17417702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 144

Similar Datasets

Genome-wide epigenetic changes of leukemia cell lines in reponse to byrostatin treatment

Project description:We report the application of cut&tag technology for high-throughput profiling of histone modifications in leuemia cells in reponse to bryostatin treatment. We generated genome-wide chromatin-state landscape of NALM6, REH and Raji cells. Dual- and tri-methylation of lysine 4 on histone H3 protein indicate genes that are actively expressed/regulated. Tri-methylation of lysine 27 on histone H3 protein marks genes that are negatively regulated or suppressed for expressiom. We compared differential peaks for cells treated with or without bryostatin to demonstrate genes responding to bryostatin treatment on epigenetic level.

2022-01-06 | GSE192965 | GEO

Epigenetic changes of Raji Epstein–Barr viral genome in reponse to byrostatin treatment

Project description:Epigenetic changes of Raji Epstein–Barr viral genome in reponse to byrostatin treatment

| PRJNA793426 | ENA

Epigenetic changes of Raji Epstein–Barr viral genome in reponse to byrostatin treatment

Project description:We report the application of cut&tag technology for high-throughput profiling of histone modifications Raji Epstein–Barr viral genome in reponse to bryostatin treatment. Dual- and tri-methylation of lysine 4 on histone H3 protein indicate genes that are actively expressed/regulated. Tri-methylation of lysine 27 on histone H3 protein marks genes that are negatively regulated or suppressed for expression.

2022-01-05 | GSE192837 | GEO

Epigenetic treatment of B-cell lymphoma cell lines

Project description:We used DNA microarray technology to assess changes in gene expression after treatment of 11 lymphoma cell lines with epigenetic drugs. We identified genes with upregulated expression in treated cell lines and with downregulated expression in B-cell lymphoma patient samples when compared to normal B cells. Assess changes in gene expression after treatment of 11 lymphoma cell lines with epigenetic drugs (aza and TSA).

2013-04-18 | E-GEOD-46064 | biostudies-arrayexpress

Epigenetic studies in Acute Myeloid Leukemia

Project description:Epigenetic studies in Acute Myeloid Leukemia

| PRJNA301478 | ENA

Epigenetic treatment of B-cell lymphoma cell lines

2013-04-18 | GSE46064 | GEO

Epigenetic subtypes of neuroblastoma [cell lines]

Project description:Epigenetic subtypes of neuroblastoma [cell lines]

| PRJNA527794 | ENA

ORY-1001/RG6016 effect on leukemia cell lines

Project description:The lysine-specific demethylase LSD1/KDM1A is a key regulator of stem cell potential in acute myeloid leukemia (AML). Inhibition of its expression or catalytic activity overcomes the differentiation block and reduces colony formation potential. We have developed ORY-1001 as highly potent and selective inhibitor of KDM1A. Treatment of AML cell lines with ORY-1001 induces accumulation of H3K4me2 marks at KDM1A target genes, compromises leukemic stem cell capacity, and provokes blast differentiation. ORY-1001 exhibits potent synergy with standard of care drugs and with inhibitors of other epigenetic targets; reduces tumor growth and extends survival in mouse xenograft models of acute leukemia. To develop tools for use in clinical trials, we selected a panel of surrogate biomarkers for pharmacodynamic analysis based on expression changes in a panel of 24 leukemia cell lines. ORY-1001/RG6016 was the first selective KDM1A inhibitor to enter the clinic and is currently being evaluated in leukemia and solid tumor clinical trials.

2018-08-19 | GSE94567 | GEO

Serum Reponse of CF1 primary MEFs , E13

Project description:Serum Reponse of CF1 primary MEFs , E13

| PRJNA510577 | ENA

Epigenetic treatment of cervical carcinoma cell lines

Project description:Four cervical carcinoma cell lines (C4I, CaSki, HeLa, SiHa) were treated with epigenetic modifying drugs 5-aza-2’-deoxycytidine and trichostatin A. Such treatment leads to reactivation of genes that are epigenetically silenced in cancer by aberrant methylation; reactivated genes were then identified by microarray profiling. Subsets consist of 2 biological repeats and 2 dye-flip experiments for each repeat for CaSki cell line, and 3 repeats, each with 2 dye-flip experiments for C4I, HeLa, Caski cell lines. The identification of reactivated genes, their selection for validation experiments, and final identification of 6 genes that are significantly more often hypermethylated in cervical carcinoma clinical specimens is described in (manuscript submitted). Keywords: other

2005-07-17 | GSE2097 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data